Federal Pharmaceuticals subsidiary obtains approval for new antibiotic product
July 22, 2025
Source: drugdu
113
On July 17, United Laboratories (03933) announced that the injection of amoxicillin sodium and clavulanate potassium (specifications: 0.6g, 1.2g) applied by the company's wholly-owned subsidiary, Zhuhai United Laboratories Co., Ltd. Zhongshan Branch, has been approved by the China National Drug Administration and successfully passed the generic drug quality and efficacy consistency evaluation. This product is a broad-spectrum penicillin antibiotic with the characteristics of significantly enhanced antibacterial activity and is suitable for the treatment of a variety of infections.
This approval will further consolidate the company's dominant position in the anti-infection field. The company said it will continue to focus on new product development and promote consistency evaluation, which is expected to create greater benefits for the company and its shareholders.
https://finance.eastmoney.com/a/202507183460816649.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
